We have observed improvement in quality of life measurements and extension of survival associated with anti-tumoral effects in patients with hepatocellular carcinoma.
We are developing this device for the safe and non-invasive palliative care treatment of patients with advanced HCC, using patient-specific frequencies (PSF).
Autem Medical device
Costa et al. Br J Cancer (2011) 105:640-8
Bruix et al. J European Journal of Cancer (2013) 49:3412–3419
Clinical trial with RF EMF in HCC
Clinical trial with Autem EMfields in HCC
Durable and meaningful tumor control.
Treatment modality supporting the concept of precise medicine in cancer.
Control of treatment compliance by physicians.
Affordable treatment cost.
Without the need and costs of identifying molecular markers.
Improvement in cancer-specific knowledge supported by integrated A.I. platform.
Symptomatic improvement related to improvement in quality of life measurement in most of the patients.
The Autem gEM medical device connects to a computer (or health cloud) to identify and load a patient-specific frequencies (PSF) treatment program into the device.
Treatment duration is 120 min, once or twice a month.
Human body becomes an antenna with very low and safe absorption levels. It is a systemic treatment.
Primary tumor and metastatic disease are destroyed by patient-specific frequencies (PSF). There is no toxicity to healthy tissues.
Want to know more?
Send us your e-mail. We will keep you updated about our innovative treatment.
Email Address *
This new medical device has not yet received regulatory approval and is not available for commercial distribution.
New Hampshire, USA
35 South Main Street, Suite 208
São Paulo, Brasil
Rua Barata Ribeiro, 398 cj.22
São Paulo, SP
+55 11 2389-8577